Cada Dennis J, Levien Terri L, Baker Danial E
Hosp Pharm. 2016 Jul;51(7):585-96. doi: 10.1310/hpj5107-585.
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The July 2016 monograph topics are pimavanserin, venetoclax, defibrotide, lifitegrast ophthalmic solution 5%, and atezolizumab. The Safety MUE is on pimavanserin.
每月,《处方集专论服务》的订阅者会收到5至6篇关于新发布或处于3期临床试验后期阶段药物的资料详实的专论。这些专论面向药学与治疗学委员会。订阅者还会每月收到1页关于对议程以及药房/护理在职培训有用药物的总结专论。每月还会提供一份全面的目标药物利用评估/药物使用评估(DUE/MUE)。订阅后,专论可供订阅者在线获取。专论可进行定制以满足机构需求。通过与《处方集》的合作,《医院药学》在本专栏发表精选评论。如需了解更多关于《处方集专论服务》的信息,请致电866 - 397 - 3433联系威科集团客服。2016年7月的专论主题为匹莫范色林、维奈托克、去纤苷、5%的lifitegrast眼用溶液和阿特珠单抗。安全性MUE针对匹莫范色林。